Current Report Filing (8-k)
28 April 2020 - 8:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): April 21, 2020
ADAMIS
PHARMACEUTICALS CORPORATION
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
11682
El Camino Real, Suite 300
San
Diego, CA
|
|
92130
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
|
|
|
|
|
|
|
Registrant’s
telephone number, including area code: (858) 997-2400
(Former
name or Former Address, if Changed Since Last Report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on
which registered
|
Common
Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
Item
8.01 Other Events
As
previously reported, on April 14, 2020, Adamis Pharmaceuticals Corporation (the “Company”) received a letter from
the Listing Qualifications Department of The NASDAQ Capital Market (“Nasdaq”) notifying the Company that it has been
granted an additional 180-day compliance period or until October 5, 2020, to regain compliance with the minimum $1.00 bid price
per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the “Rule”). On April 21, 2020, the Company received
an additional notice from Nasdaq (the “Tolling Notice”), which stated that, due to current market conditions, Nasdaq
has determined to toll the compliance period for the Rule through June 30, 2020. As a result, the new date by which the Company
has to regain compliance with the Rule is December 21, 2020.
The
Tolling Notice does not impact the Company’s listing on The Nasdaq Capital Market at this time. To regain compliance, the
closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business
days at any time prior to December 21, 2020.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: April 27, 2020
|
By:
|
/s/
Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial
Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2024 to May 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From May 2023 to May 2024